DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for subcortical band heterotopia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSubcortical band heterotopia maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for subcortical band heterotopia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
platelet activating factor acetylhydrolase 1b regulatory subunit 1 (PAFAH1B1) — PAFAH1B1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9E0Z · 2.86 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A 2018 case report describes a 22-year-old woman with subcortical band heterotopia who presented with refractory seizure and speech regression. Her MRI showed double cortex and her EEG showed frontal intermittent rhythmic delta activity. The report notes that subcortical band heterotopia is predominantly a disease of females and usually presents with refractory seizure and varying degrees of mental retardation, attributing the condition to mutation in the DCX or LIS1 gene.
A 2005 review states that the genetic basis of approximately 80% of typical subcortical band heterotopia is known, with most cases due to abnormalities in the LIS1 or DCX genes, ranging from single basepair substitutions to contiguous gene deletions. The review describes a robust correlation between clinical aspects of the disorder and the type and location of mutations in the affected gene, allowing clinicians to predict which gene is likely affected based on clinical and imaging features.
A 2014 study using a mouse model of neocortical molecular layer heterotopia—a related neuronal migration defect—identified diverse excitatory and inhibitory neurons as well as glia within the heterotopia based on molecular profiles. The study documented diverse afferents from subcortical neuromodulatory centres and intracortical projections to and from the heterotopia, noting that these data are relevant to understanding how heterotopia affect brain function in neurodevelopmental disorders.
No drug treatment is mentioned in any of these abstracts. What is missing is any clinical trial testing a therapy for subcortical band heterotopia, any animal model study that tests a pharmacological intervention, and any patient stratification beyond the known genetic subtypes. The field lacks funded studies that move from describing the genetic and cellular pathology to testing whether any existing or novel compound can alter the course of the epilepsy or developmental delay.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Child Neurology · 2005 · 41 citations
Topical Review: Genotype-Phenotype Correlation in Lissencephaly and Subcortical Band Heterotopia: The Key Questions Answered
AbstractLissencephaly and subcortical band heterotopia are closely related cortical malformations and are true disorders of neuronal migration. The genetic basis of approximately 70% of classic lissencephaly and 80% of typical subcortical band heterotopia is known. Most are due to abnormalities within the LIS1 or DCX genes, with abnormalities ranging from single basepair substitutions to contiguous gene deletions. Understanding the genetic basis of these disorders has led to the elucidation of the molecular and developmental mechanisms that are adversely affected. There is a robust correlation between many of the clinical aspects of lissencephaly or subcortical band heterotopia and the type and location of mutations in the affected gene. Using this knowledge, the clinician can predict with some accuracy which gene is likely to be affected based on the clinical and imaging features. This review answers some of the key questions regarding the genotype-phenotype correlation for lissencephaly and subcortical band heterotopia.
Developmental Neuroscience · 2014 · 13 citations · open access
Cellular and Axonal Constituents of Neocortical Molecular Layer Heterotopia
AbstractHuman neocortical molecular layer heterotopia consist of aggregations of hundreds of neurons and glia in the molecular layer (layer I) and are indicative of neuronal migration defect. Despite having been associated with dyslexia, epilepsy, cobblestone lissencephaly, polymicrogyria, and Fukuyama muscular dystrophy, a complete understanding of the cellular and axonal constituents of molecular layer heterotopia is lacking. Using a mouse model, we identify diverse excitatory and inhibitory neurons as well as glia in heterotopia based on molecular profiles. Using immunocytochemistry, we identify diverse afferents in heterotopia from subcortical neuromodulatory centers. Finally, we document intracortical projections to/from heterotopia. These data are relevant toward understanding how heterotopia affect brain function in diverse neurodevelopmental disorders.
Bangladesh Journal of Neuroscience · 2018 · 0 citations · open access
A Case of Subcortical Band Heterotopia Presented with Epilepsy and Speech Regression
AbstractSubcortical Heterotopia is a rare developmental disorder of human brain due to mutation in the DCX or LIS1gene.It is predominantly a disease of female. It usually present with refractory seizure and varying degree of mental retardation. Here a case of 22 years lady who presented with refractory seizure is reported. Her MRI revealed Double cortex and her EEG revealed Frontal intermittent rhythmic delta activity (FIRDA). Bangladesh Journal of Neuroscience 2018; Vol. 34 (2): 106-109
International Journal of Current Research and Review · 2017 · 0 citations · open access
Role of Subcortical Band Heterotopia in Epileptogenesis - Case Report
AbstractBand heterotopias are one of the rarest groups of congenital disorder that result in variable degree of structural abnormality of brain parenchyma. Band of heterotopic neurons result from a congenital or acquired deficiency of the neuronal migration. We report a case of 15 year old female patient with subcortical band heterotopia in which disease manifested itself in first decade of life without any such family history.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
